Fig. 6From: A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancerT-PNU promotes long-lasting immune protection. a, Outline of a representative rechallenge experiment. b, EMT6-hHER2 tumor-free animals after T-PNU treatment were rechallenged with EMT6-hHER2, EMT6-WT and TS/A Thy1.1 cancer cells. P-value < 0.0005 *** (Gehan-Breslow-Wilcoxon Test). c, Tumor growth of untreated controls. d, Overall survival curves of b and cBack to article page